CoChat

The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies

Open access
Jerlhag, Elisabet · 2023 · Frontiers in Pharmacology

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Abstract

Although the multifaceted mechanisms underlying alcohol use disorder (AUD) have been partially defined, the neurobiological complexity of this disorder is yet to be unraveled. One of the systems that have gained attention in recent times is the gut–brain axis. Although numerous peptides participate in this axis, glucagon-like peptide-1 (GLP-1) plays a central role. GLP-1 is a crucial anorexigenic peptide, with potent abilities to reduce food intake and body weight. The physiological complexity of GLP-1 entails glucose homeostasis, gastrointestinal motility, and the release of insulin and glucagon. As reviewed in this study, acute or repeated treatment with GLP-1 receptor (GLP-1R) agonists decreases alcohol consumption in rodents. Moreover, the abilities of alcohol to promote hyperlocomotion, dopamine release in the nucleus accumbens, and reward in the conditioned place preference paradigm are all suppressed by GLP-1R ligands. Moreover, activation of GLP-1R suppresses the motivation to consume alcohol, alcohol-seeking behaviors, and relapse drinking in male rodents. Similarly, abstinence symptoms experienced during alcohol withdrawal are attenuated by activation of the GLP-1 pathway. On a similar note, the activation of GLP-1 receptors within areas of the brain that are processing reward modulates these alcohol-related responses. Another area that is crucial for this ability is the nucleus of the solitary tract, which is where GLP-1 is produced and from which GLP-1-containing neurons project to areas of reward. These findings may have clinical relevance as AUD is associated with polymorphisms in GLP-1-related genes. Although a GLP-1R agonist does not alter alcohol intake in AUD patients, it reduces this consumption in a sub-population of obese AUD individuals. Given the uncertainty of this outcome, additional clinical studies of obese AUD patients should explore the effects of the GLP-1R agonists on alcohol intake and body weight. Furthermore, GLP-1 receptors modulate the behavioral and neurochemical responses to addictive drugs. Taken together, these preclinical and clinical findings imply that the GLP-1 pathway plays a role in the complex mechanisms regulating alcohol and drug consumption patterns, unveiling a novel aspect of addiction medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2023.1063033

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Schematic illustration of alcohol-related responses that are reduced (↓) by GLP-1 receptor agonists; the illustration is created using bioreder.com.
FIGURE 1 Schematic illustration of alcohol-related responses that are reduced (↓) by GLP-1 receptor agonists; the illustration is created using bioreder.com.CC BY · PubMed Central
FIGURE 2 Schematic illustration of selected areas in which GLP-1 receptor agonists act to regulate alcohol-related responses in rodents. Indicated are the nucleus of the solitary tract (NTS), nucleus accumbens (NAc), ventral tegmental area (VTA), anterior VTA (aVTA), posterior VTA (pVTA), laterodorsal tegmental area (LDTg), and GLP-1 receptor agonists (GLP-1RA); the illustration is created using bioreder.com.
FIGURE 2 Schematic illustration of selected areas in which GLP-1 receptor agonists act to regulate alcohol-related responses in rodents. Indicated are the nucleus of the solitary tract (NTS), nucleus accumbens (NAc), ventral tegmental area (VTA), anterior VTA (aVTA), posterior VTA (pVTA), laterodorsal tegmental area (LDTg), and GLP-1 receptor agonists (GLP-1RA); the illustration is created using bioreder.com.CC BY · PubMed Central
FIGURE 3 Schematic illustration of various drug-related responses that are reduced (↓) or unaltered (≠) by GLP-1 receptor agonists. Abbreviated are the nucleus of the solitary tract (NTS), medial habenula (MH), interpeduncular nucleus (IPN), nucleus accumbens (NAc), ventral tegmental area (VTA), laterodorsal tegmental area (LDTg), and intravenous (IV); the illustration is created using bioreder.com.
FIGURE 3 Schematic illustration of various drug-related responses that are reduced (↓) or unaltered (≠) by GLP-1 receptor agonists. Abbreviated are the nucleus of the solitary tract (NTS), medial habenula (MH), interpeduncular nucleus (IPN), nucleus accumbens (NAc), ventral tegmental area (VTA), laterodorsal tegmental area (LDTg), and intravenous (IV); the illustration is created using bioreder.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Research works printed but not linked: 1

  1. Kalra, 2011, Change in alcohol consumption following liraglutide initiation: A real life experience, 2019

Cited by

See all 89

Metadata

Authors
Jerlhag, E.
Affiliations
University of Gothenburg (SE)
Corresponding author
Jerlhag, Elisabet
Venue
Frontiers in Pharmacology
Published
2023-03-30
Volume
14
Pages
1063033-1063033
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4361280631
Cited by
80
References
80
Citations by year
2026: 17 · 2025: 36 · 2024: 20 · 2023: 7
FWCI
3.08
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Vetenskapsrådet
  • Hjärnfonden
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, alcoholism, addiction, gut-brain axis, alcohol withdrawal, nucleus tractus solitarius, nucleus accumbens dopamine, conditioned place preference, alcohol relapse, obesity, genetic polymorphism, drug addiction, anorexigenic peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. https://app.cochat.ai/papers/10.3389/fphar.2023.1063033
The paper
Jerlhag, E. (2023). The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1063033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.